All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How does transfusion independence impact survival outcomes with momelotinib in MF?
Bookmark this article
During ASCO and EHA 2021, the MPN Hub spoke with Ruben A Mesa, UT Health San Antonio, San Antonio, US. We asked, How does transfusion independence impact survival outcomes with momelotinib in myelofibrosis (MF)?
How does transfusion independence impact survival outcomes with momelotinib in MF?
Momelotinib is a JAKi that attenuates anemia in patients with MF. Mesa describes an analysis of the SIMPLIFY-1 study, comparing momelotinib with ruxolitinib in the frontline setting, and presents the correlation between transfusion-independent response and overall survival (OS) with momelotinib treatment.
More about...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox